Jpmorgan Chase & CO Taysha Gene Therapies, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,003,067 shares of TSHA stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,003,067
Previous 2,643,755
62.06%
Holding current value
$2.72 Million
Previous $4.57 Million
69.52%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding TSHA
# of Institutions
127Shares Held
151MCall Options Held
70KPut Options Held
4.7K-
Avoro Capital Advisors LLC New York, NY20MShares$54.2 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$50.9 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$45.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$31.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$29.5 Million0.31% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $131M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...